151 related articles for article (PubMed ID: 2565860)
1. Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist.
Fullarton GM; McLauchlan G; Macdonald A; Crean GP; McColl KE
Gut; 1989 Apr; 30(4):449-54. PubMed ID: 2565860
[TBL] [Abstract][Full Text] [Related]
2. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine.
Fullarton GM; Macdonald AM; McColl KE
Aliment Pharmacol Ther; 1991 Aug; 5(4):391-8. PubMed ID: 1685675
[TBL] [Abstract][Full Text] [Related]
3. Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h.
Lanzon-Miller S; Pounder RE; Chronos NA; Raymond F; Hamilton MR; Dalgleish D
Gut; 1988 Oct; 29(10):1364-9. PubMed ID: 2904394
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of 24-hour acidity by nizatidine].
Dammann HG; Dreyer M; Gottlieb WR; Wolf N; Müller P; Simon B
Fortschr Med; 1989 May; 107(14):321-4. PubMed ID: 2568971
[TBL] [Abstract][Full Text] [Related]
5. The 24-hour acid suppression profile of nizatidine.
Dammann HG; Gottlieb WR; Walter TA; Müller P; Simon B; Keohane P
Scand J Gastroenterol Suppl; 1987; 136():56-60. PubMed ID: 2892256
[TBL] [Abstract][Full Text] [Related]
6. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
[TBL] [Abstract][Full Text] [Related]
7. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.
Nwokolo CU; Smith JT; Sawyerr AM; Pounder RE
Gut; 1991 Dec; 32(12):1455-60. PubMed ID: 1685465
[TBL] [Abstract][Full Text] [Related]
8. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine.
Nwokolo CU; Smith JT; Gavey C; Sawyerr A; Pounder RE
Aliment Pharmacol Ther; 1990; 4 Suppl 1():29-45. PubMed ID: 1983345
[TBL] [Abstract][Full Text] [Related]
9. Lack of gastric acid rebound after stopping a successful short-term course of nizatidine in duodenal ulcer patients.
Savarino V; Mela GS; Zentilin P; Sumberaz A; Bonifacino G; Celle G
Am J Gastroenterol; 1991 Mar; 86(3):281-4. PubMed ID: 1671805
[TBL] [Abstract][Full Text] [Related]
10. The effect of an oral evening dose of nizatidine on nocturnal and peptone-stimulated gastric acid and gastrin secretion.
Kovacs TO; Van Deventer GM; Maxwell V; Sytnik B; Walsh JH
Scand J Gastroenterol Suppl; 1987; 136():41-6. PubMed ID: 2892254
[TBL] [Abstract][Full Text] [Related]
11. Marked rebound acid hypersecretion after treatment with ranitidine.
el-Omar E; Banerjee S; Wirz A; Penman I; Ardill JE; McColl KE
Am J Gastroenterol; 1996 Feb; 91(2):355-9. PubMed ID: 8607506
[TBL] [Abstract][Full Text] [Related]
12. [Effect of Famotidine in gastric acidity, plasma secretin and gastrin in duodenal ulcer patients. With reference to 24-hour intragastric pH monitoring].
Shiratori K; Watanabe S; Maruyama M; Itoh Y; Adachi H; Kurokawa K; Takeuchi T
Nihon Shokakibyo Gakkai Zasshi; 1984 Mar; 81(3):855-63. PubMed ID: 6146733
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of oral nizatidine.
Vargas R; Ryan J; McMahon FG; Regel G; Offen WW; Matsumoto C
J Clin Pharmacol; 1988 Jan; 28(1):71-5. PubMed ID: 2895125
[TBL] [Abstract][Full Text] [Related]
14. Effect of oral famotidine on 24-hour intragastric acidity.
Santana IA; Lanzon-Miller S; Pounder RE
Postgrad Med J; 1986; 62 Suppl 2():39-42. PubMed ID: 2890150
[TBL] [Abstract][Full Text] [Related]
15. The effects of 15 days of dosing with placebo, sufotidine 600 mg nocte or sufotidine 600 mg twice daily upon 24-hour intragastric acidity and 24-hour plasma gastrin.
Rogers MJ; Holmfield JH; Primrose JN; Johnston D
Aliment Pharmacol Ther; 1990; 4 Suppl 1():65-74. PubMed ID: 1983347
[TBL] [Abstract][Full Text] [Related]
16. The effect of SK&F 94482 (BMY-25368) on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects.
Gavey CJ; Smith JT; Nwokolo CU; Pounder RE
Aliment Pharmacol Ther; 1989 Dec; 3(6):557-64. PubMed ID: 2577500
[TBL] [Abstract][Full Text] [Related]
17. Effect of a new potent H2-receptor antagonist on meal-stimulated gastric acid secretion and serum gastrin concentration in duodenal ulcer patients.
Brozinsky S; Hogan DL; Isenberg JI; Richardson CT
Dig Dis Sci; 1984 Feb; 29(2):129-33. PubMed ID: 6141898
[TBL] [Abstract][Full Text] [Related]
18. Acid inhibitory characteristics of nizatidine in man: an overview.
Parente F; Bianchi Porro G
Scand J Gastroenterol Suppl; 1994; 206():3-7. PubMed ID: 7863250
[TBL] [Abstract][Full Text] [Related]
19. Interrelationship between gastric acidity and gastrin concentration in patients with duodenal or gastric ulcer and in healthy subjects.
Mahachai V; Walker K; Pinchbeck B; Thomson AB
Clin Ther; 1985; 7(4):424-41. PubMed ID: 4016826
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.
Savarino V; Mela GS; Zentilin P; Scalabrini P; Bonifacino G; Gambaro P; Celle G
Digestion; 1989; 42(1):1-6. PubMed ID: 2568299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
